These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 21475175

  • 1. Fix the antibiotics pipeline.
    Cooper MA, Shlaes D.
    Nature; 2011 Apr 07; 472(7341):32. PubMed ID: 21475175
    [No Abstract] [Full Text] [Related]

  • 2. The drug push.
    Servick K.
    Science; 2015 May 22; 348(6237):850-3. PubMed ID: 25999488
    [No Abstract] [Full Text] [Related]

  • 3. Examining Manufacturing Readiness for Breakthrough Drug Development.
    Dye E, Sturgess A, Maheshwari G, May K, Ruegger C, Ramesh U, Tan H, Cockerill K, Groskoph J, Lacana E, Lee S, Miksinski SP.
    AAPS PharmSciTech; 2016 Jun 22; 17(3):529-38. PubMed ID: 26608693
    [No Abstract] [Full Text] [Related]

  • 4. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M, Mossialos E.
    Expert Opin Drug Discov; 2018 Oct 22; 13(10):889-892. PubMed ID: 30175625
    [No Abstract] [Full Text] [Related]

  • 5. Drug development: Time for teamwork.
    May M.
    Nature; 2014 May 01; 509(7498):S4-5. PubMed ID: 24784427
    [No Abstract] [Full Text] [Related]

  • 6. Antibacterial R&D incentives.
    Laxminarayan R, Powers JH.
    Nat Rev Drug Discov; 2011 Sep 30; 10(10):727-8. PubMed ID: 21959280
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antibiotics: a shot in the arm.
    Leeb M.
    Nature; 2004 Oct 21; 431(7011):892-3. PubMed ID: 15496888
    [No Abstract] [Full Text] [Related]

  • 9. A three-step plan for antibiotics.
    Nature; 2014 May 29; 509(7502):533. PubMed ID: 24877183
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The GAIN Act legislation to combat antimicrobial resistance: Where do we stand?
    Sfeir MM.
    Infect Control Hosp Epidemiol; 2018 Dec 29; 39(12):1499-1500. PubMed ID: 30334503
    [No Abstract] [Full Text] [Related]

  • 12. Re-engineering drug discovery and development.
    FitzGerald GA.
    LDI Issue Brief; 2011 Oct 29; 17(2):1-4. PubMed ID: 22049582
    [Abstract] [Full Text] [Related]

  • 13. Biotech entrepreneurs swoon over proposed fundraising changes.
    Venkataramanan M.
    Nat Med; 2012 Jan 06; 18(1):3. PubMed ID: 22227645
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL, Myers RT, Goodsaid F.
    Clin Pharmacol Ther; 2010 May 06; 87(5):530-3. PubMed ID: 20407457
    [Abstract] [Full Text] [Related]

  • 16. In the midst of the antimicrobial discovery conundrum: an overview.
    Tomaras AP, Dunman PM.
    Curr Opin Microbiol; 2015 Oct 06; 27():103-7. PubMed ID: 26356257
    [No Abstract] [Full Text] [Related]

  • 17. Report urges controversial 'delinkage' to foster new antibiotics.
    Holmes D.
    Nat Med; 2014 Apr 06; 20(4):320. PubMed ID: 24710363
    [No Abstract] [Full Text] [Related]

  • 18. Q&A: Bernard Munos.
    Bender E.
    Nature; 2016 May 12; 533(7602):S59. PubMed ID: 27167392
    [No Abstract] [Full Text] [Related]

  • 19. Medicine. Can intellectual property save drug development?
    FitzGerald GA.
    Science; 2012 Oct 26; 338(6106):483-4. PubMed ID: 23112323
    [No Abstract] [Full Text] [Related]

  • 20. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B, Bartlett J, Wunderink R, Gilbert DN.
    Am J Respir Crit Care Med; 2015 Jan 15; 191(2):135-40. PubMed ID: 25590154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.